Fulcrum Therapeutics, Inc.
NASDAQ:FULC · NASDAQ Global Market
+$0.06 today
Vol 6.05M · Avg 1.78M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NASDAQ:FULC · Revenue to Net Income
Key Ratios
Analysis
$0 of revenue converted into -$76.1M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-1.15, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 -100.0% | $80.0M +2752.0% | $2.8M -55.8% | $6.3M -66.9% | $19.2M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $1.4M -97.8% | $63.4M -11.7% | $71.8M -6.5% | $76.8M +10.2% | $69.7M | $725.6M | $804.0M | $882.4M |
| Gross Profit | -$1.4M -108.4% | $16.6M +124.1% | -$69.0M +2.0% | -$70.4M -39.4% | -$50.5M | $8.9B | $7.6B | $6.2B |
| Gross Margin | — | 20.8% +2480.5pp | -2459.8% -1349.1pp | -1110.7% -847.0pp | -263.7% | 9.8% | 28.9% | 38.3% |
| Research & Development | $56.1M -11.5% | $63.4M -11.7% | $71.8M -6.5% | $76.8M +10.2% | $69.7M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $28.7M -21.4% | $36.4M -12.5% | $41.7M -0.1% | $41.7M +36.6% | $30.5M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $83.4M +116.5% | $38.5M -7.6% | $41.7M -1.1% | $42.1M +38.0% | $30.5M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $1.4M -12.7% | $1.6M -26.7% | $2.2M -10.0% | $2.4M -4.0% | $2.5M | $374.2M | $1.2B | $631.8M |
| EBITDA | -$73.5M -302.9% | -$18.2M +80.8% | -$95.2M +13.3% | -$109.7M -40.1% | -$78.3M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | — | -22.8% +3369.8pp | -3392.6% -1662.6pp | -1730.1% -1321.3pp | -408.8% | 5.6% | 46.3% | 42.0% |
| Operating Income | -$84.8M -287.1% | -$21.9M +80.2% | -$110.7M +1.7% | -$112.6M -38.9% | -$81.1M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | — | -27.4% +3917.9pp | -3945.2% -2170.4pp | -1774.9% -1351.9pp | -423.0% | 16.6% | 24.1% | 22.0% |
| Interest Income | $0 | $0 | $0 | $0 -100.0% | $207.0K | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $0 | $0 | $0 | $0 | $0 | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | $9.9M -18.8% | $12.2M -8.7% | $13.3M +395.5% | $2.7M +1199.5% | $207.0K | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$74.9M -670.0% | -$9.7M +90.0% | -$97.3M +11.4% | -$109.9M -35.9% | -$80.8M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | — | -12.2% +3457.9pp | -3470.1% -1737.6pp | -1732.4% -1310.5pp | -421.9% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $1.3B | -$1.6B | $745.2M |
| Net Income | -$74.9M -670.0% | -$9.7M +90.0% | -$97.3M +11.4% | -$109.9M -35.9% | -$80.8M | $4.9B | $4.8B | $4.7B |
| Net Margin | — | -12.2% +3457.9pp | -3470.1% -1737.6pp | -1732.4% -1310.5pp | -421.9% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$1 -637.5% | -$0 +89.9% | -$2 +32.3% | -$2 -5.9% | -$2 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$1 -637.5% | -$0 +89.9% | -$2 +32.3% | -$2 -5.9% | -$2 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $63.4M +2.2% | $62.0M +1.1% | $61.3M +36.3% | $45.0M +27.2% | $35.4M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $63.4M +2.2% | $62.0M +1.1% | $61.3M +36.3% | $45.0M +27.2% | $35.4M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
RAPT Therapeutics, Inc.
RAPT
$959.26M
Lexicon Pharmaceuticals, Inc.
NASDAQ:LXRX
$890.61M
Omeros Corporation
NASDAQ:OMER
$746.62M
Neurogene Inc.
NASDAQ:NGNE
$498.58M
Ocugen, Inc.
NASDAQ:OCGN
$428.23M
Lineage Cell Therapeutics, Inc.
AMEX:LCTX
$301.65M
Compass Therapeutics, Inc.
NASDAQ:CMPX
$281.27M
Neumora Therapeutics, Inc. Common Stock
NASDAQ:NMRA
$279.78M
Bicycle Therapeutics plc
NASDAQ:BCYC
$277.23M
ADC Therapeutics S.A.
NYSE:ADCT
$139.27M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does FULC generate?
Fulcrum Therapeutics, Inc. (FULC) reported $0.00 of revenue in fiscal 2025.
Is FULC profitable?
Fulcrum Therapeutics, Inc. (FULC) reported -$74,880,000.00 of net income.
Explore More
Continue the stock analysis
Jump to another research area for this company.